Regencell Bioscience Holdings Limited
RGC
$34.61
$0.270.79%
NASDAQ
| 06/30/2024 | 03/31/2024 | 06/30/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -5.91% | 39.06% | 128.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -17.64% | 58.15% | 147.91% |
| Operating Income | -- | -- | 17.64% | -58.15% | -147.91% |
| Income Before Tax | -- | -- | 20.18% | -55.21% | -146.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 20.18% | -55.21% | -146.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 28.67% | 150.74% | 371.22% |
| Net Income | -- | -- | 21.15% | -53.81% | -144.13% |
| EBIT | -- | -- | 17.64% | -58.15% | -147.91% |
| EBITDA | -- | -- | 19.48% | -56.48% | -147.14% |
| EPS Basic | -- | -- | 22.37% | -40.79% | -115.97% |
| Normalized Basic EPS | -- | -- | 26.99% | -181.04% | -142.48% |
| EPS Diluted | -- | -- | 22.37% | -40.79% | -115.97% |
| Normalized Diluted EPS | -- | -- | 26.99% | -181.04% | -142.48% |
| Average Basic Shares Outstanding | -- | -- | 1.62% | 15.25% | 21.26% |
| Average Diluted Shares Outstanding | -- | -- | 1.62% | 15.25% | 21.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |